The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study

Autores
Martín, Andrea P.; Urrets Zavalía, Julio; Berra, Alejandro; Gallino, Norberto; Gómez Demel, Eduardo; Gagliardi, Julio; Mariani, Ana Lía; Baena Cagnani, Carlos E.; Urrets Zavalía, Enrique Alberto; Serra, Horacio M.
Año de publicación
2003
Idioma
español castellano
Tipo de recurso
artículo
Estado
versión aceptada
Descripción
Background: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical markers of inflammation on conjunctival cells in patients with AC. Methods: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness, increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during thirty days. They were studied by measuring clinical and immunologic parameters. Results: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped significantly in 68% and 73% of them (p < 0.0062 and [removed] Indications:19 patients with allergic conjunctivitis with symptoms of itching, tearing, burning, redness and signs of increased watery discharge, swelling, and presence of follicles. Coexisting diseases were hay fever, asthmatic bronchitis and dermatitis. Patients:19 patients, 8 males and 11 females, aged between 6 and 63 years. TypeofStudy:An open, uncontrolled study investigating the effect of Zaditen administration on biochemical markers of inflammation on conjunctival cells in patients with allergic conjunctivitis (AC). DosageDuration:One drop of 0.05% ophthalmic emulsion on both eyes topically (twice daily instillations). Duration: 30 days. One drop of 0.05% eye drops topically bid to both eyes. Duration: 30 days. Results:After 7 days of treatment, 10 (53%) patients showed improvements of their symptoms and signs (p < 0.0001). With continued treatment through day 14, symptoms control was achieved in 14 (76%) patients (p < 0.0001). Moreover, administration of 0.05% Zaditen eye drops for 30 days significantly (p < 0.0001) reduced the TSSS for each patient between days 0 and 30. Treatment with this drug had clinical effects on burning, watery discharge, and swelling, particularly, at the end of the treatment. Every other symptom was significantly reduced (p < 0.016) at any time of clinical evaluation. The effect of the treatment was also studied on the expression of different molecules on CD45 negative cells by fluorescence activated cell sorting (FACS). It is worth to note that cells studied which were obtained by conjunctival scraping never contained more than 3% of CD45+ cells. When the expression of HLA-DR, CD29 and eotaxin on EC was evaluated after the treatment, a drop in the percentage of those positive EC in 58%, 68% and 73% of patients, respectively was found. Although the variation in percentage of HLA-DR+ conjunctival EC was not significant, the percentage of CD29+ and eotaxin + EC significantly decreased (p < 0.0062 and < 0.0082, respectively) at the end of the treatment. In 9/19 patients a simultaneous drop in EC positive for CD29 and eotaxin was observed. No correlation between variations in mean fluorescent intensity and percentage of positive EC for these markers before and after the treatment was found. FreeText:All patients had a history of allergy. Different symptoms (itching, tearing, burning, redness) and signs (watery discharge increase, swelling, presence of follicles) of allergic conjunctivitis were evaluated at their enrollment (day zero) and at different times after starting treatment (7, 15 and 30 days). Symptoms and signs were classified in four stages: 0-Absent; 1-Mild; 2-Moderate and 3-Severe. The total symptoms and signs score (TSSS) for each subject were obtained by adding the values of each symptoms and signs divided by the total number of them. Samples of conjunctival scrapings were collected from both eyes of all patients treated on days 0 and 30 using a disposable plastic scoop. Tests: CD29, HLA-DR antigen, and eotaxin expression in conjunctival epithelial cells (EC). AdverseEffects:No adverse events were mentioned. AuthorsConclusions:Here, we corroborated the effectiveness of ketotifen fumarate in decreasing the symptoms and signs of AC in the majority of patients, but more importantly we showed that this drug even though was not effective in reducing the expression of HLA-DR on EC, it significantly decreased the percentage of CD29+ and eotaxin+ EC.
Fil: Martín, Andrea P. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Urrets Zavalía, Julio. Universidad Católica de Córdoba. Facultad de Ciencias Médicas; Argentina
Fil: Berra, Alejandro. Dpto. de Patología, Facultad Medicina, Universidad de Buenos Aires, Argentina
Fil: Gallino, Norberto. Inmunología, Universidad Nacional de Misiones, Argentina
Fil: Gómez Demel, Eduardo. Servicio de Oftalmología, Hospital Privado, Córdoba, Argentina
Fil: Gagliardi, Julio. Servicio de Alergia e Inmunologia, Hospital Privado, Córdoba, Argentina
Fil: Mariani, Ana Lía. Inmunología, Universidad Nacional de Misiones, Argentina
Fil: Baena Cagnani, Carlos E. Servicio de Pediatría, Hospital Infantil Municipal, Córdoba, Argentina
Fil: Urrets Zavalía, Enrique Alberto. Universidad Católica de Córdoba. Facultad de Ciencias Médicas; Argentina
Fil: Serra, Horacio M. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina
Fuente
Martín, Andrea P., Urrets Zavalía, Julio ORCID: https://orcid.org/0000-0003-2267-2783 , Berra, Alejandro, Gallino, Norberto, Gómez Demel, Eduardo, Gagliardi, Julio, Mariani, Ana Lía, Baena Cagnani, Carlos E., Urrets Zavalía, Enrique Alberto and Serra, Horacio M. ORCID: https://orcid.org/0000-0003-4979-8642 (2003) The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. BMC Ophthalmology, 3. pp. 1-8. ISSN 1471-2415
Materia
R Medicina (General)
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
Repositorio
Producción Académica (UCC)
Institución
Universidad Católica de Córdoba
OAI Identificador
oai:pa.bibdigital.uccor.edu.ar:3972

id PAUCC_c37844367f387b22a66967fae1190d07
oai_identifier_str oai:pa.bibdigital.uccor.edu.ar:3972
network_acronym_str PAUCC
repository_id_str 2718
network_name_str Producción Académica (UCC)
spelling The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled studyMartín, Andrea P.Urrets Zavalía, JulioBerra, AlejandroGallino, NorbertoGómez Demel, EduardoGagliardi, JulioMariani, Ana LíaBaena Cagnani, Carlos E.Urrets Zavalía, Enrique AlbertoSerra, Horacio M.R Medicina (General)Background: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical markers of inflammation on conjunctival cells in patients with AC. Methods: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness, increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during thirty days. They were studied by measuring clinical and immunologic parameters. Results: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped significantly in 68% and 73% of them (p < 0.0062 and [removed] Indications:19 patients with allergic conjunctivitis with symptoms of itching, tearing, burning, redness and signs of increased watery discharge, swelling, and presence of follicles. Coexisting diseases were hay fever, asthmatic bronchitis and dermatitis. Patients:19 patients, 8 males and 11 females, aged between 6 and 63 years. TypeofStudy:An open, uncontrolled study investigating the effect of Zaditen administration on biochemical markers of inflammation on conjunctival cells in patients with allergic conjunctivitis (AC). DosageDuration:One drop of 0.05% ophthalmic emulsion on both eyes topically (twice daily instillations). Duration: 30 days. One drop of 0.05% eye drops topically bid to both eyes. Duration: 30 days. Results:After 7 days of treatment, 10 (53%) patients showed improvements of their symptoms and signs (p < 0.0001). With continued treatment through day 14, symptoms control was achieved in 14 (76%) patients (p < 0.0001). Moreover, administration of 0.05% Zaditen eye drops for 30 days significantly (p < 0.0001) reduced the TSSS for each patient between days 0 and 30. Treatment with this drug had clinical effects on burning, watery discharge, and swelling, particularly, at the end of the treatment. Every other symptom was significantly reduced (p < 0.016) at any time of clinical evaluation. The effect of the treatment was also studied on the expression of different molecules on CD45 negative cells by fluorescence activated cell sorting (FACS). It is worth to note that cells studied which were obtained by conjunctival scraping never contained more than 3% of CD45+ cells. When the expression of HLA-DR, CD29 and eotaxin on EC was evaluated after the treatment, a drop in the percentage of those positive EC in 58%, 68% and 73% of patients, respectively was found. Although the variation in percentage of HLA-DR+ conjunctival EC was not significant, the percentage of CD29+ and eotaxin + EC significantly decreased (p < 0.0062 and < 0.0082, respectively) at the end of the treatment. In 9/19 patients a simultaneous drop in EC positive for CD29 and eotaxin was observed. No correlation between variations in mean fluorescent intensity and percentage of positive EC for these markers before and after the treatment was found. FreeText:All patients had a history of allergy. Different symptoms (itching, tearing, burning, redness) and signs (watery discharge increase, swelling, presence of follicles) of allergic conjunctivitis were evaluated at their enrollment (day zero) and at different times after starting treatment (7, 15 and 30 days). Symptoms and signs were classified in four stages: 0-Absent; 1-Mild; 2-Moderate and 3-Severe. The total symptoms and signs score (TSSS) for each subject were obtained by adding the values of each symptoms and signs divided by the total number of them. Samples of conjunctival scrapings were collected from both eyes of all patients treated on days 0 and 30 using a disposable plastic scoop. Tests: CD29, HLA-DR antigen, and eotaxin expression in conjunctival epithelial cells (EC). AdverseEffects:No adverse events were mentioned. AuthorsConclusions:Here, we corroborated the effectiveness of ketotifen fumarate in decreasing the symptoms and signs of AC in the majority of patients, but more importantly we showed that this drug even though was not effective in reducing the expression of HLA-DR on EC, it significantly decreased the percentage of CD29+ and eotaxin+ EC.Fil: Martín, Andrea P. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; ArgentinaFil: Urrets Zavalía, Julio. Universidad Católica de Córdoba. Facultad de Ciencias Médicas; ArgentinaFil: Berra, Alejandro. Dpto. de Patología, Facultad Medicina, Universidad de Buenos Aires, ArgentinaFil: Gallino, Norberto. Inmunología, Universidad Nacional de Misiones, ArgentinaFil: Gómez Demel, Eduardo. Servicio de Oftalmología, Hospital Privado, Córdoba, ArgentinaFil: Gagliardi, Julio. Servicio de Alergia e Inmunologia, Hospital Privado, Córdoba, ArgentinaFil: Mariani, Ana Lía. Inmunología, Universidad Nacional de Misiones, ArgentinaFil: Baena Cagnani, Carlos E. Servicio de Pediatría, Hospital Infantil Municipal, Córdoba, ArgentinaFil: Urrets Zavalía, Enrique Alberto. Universidad Católica de Córdoba. Facultad de Ciencias Médicas; ArgentinaFil: Serra, Horacio M. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina2003-01-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://pa.bibdigital.ucc.edu.ar/3972/1/A_Mart%C3%ADn_UrretsZavalia_Berra_Mariani_Gallino_G%C3%B3mezDemel_Galiardo_BaenaCagnani_UrretsZavalia_Serra.pdf Martín, Andrea P., Urrets Zavalía, Julio ORCID: https://orcid.org/0000-0003-2267-2783 <https://orcid.org/0000-0003-2267-2783>, Berra, Alejandro, Gallino, Norberto, Gómez Demel, Eduardo, Gagliardi, Julio, Mariani, Ana Lía, Baena Cagnani, Carlos E., Urrets Zavalía, Enrique Alberto and Serra, Horacio M. ORCID: https://orcid.org/0000-0003-4979-8642 <https://orcid.org/0000-0003-4979-8642> (2003) The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. BMC Ophthalmology, 3. pp. 1-8. ISSN 1471-2415 reponame:Producción Académica (UCC)instname:Universidad Católica de Córdobaspahttp://pa.bibdigital.ucc.edu.ar/3972/info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2415-3-2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es2025-09-29T14:29:44Zoai:pa.bibdigital.uccor.edu.ar:3972instacron:UCCInstitucionalhttp://pa.bibdigital.uccor.edu.ar/Universidad privadaNo correspondehttp://pa.bibdigital.uccor.edu.ar/cgi/oai2bibdir@uccor.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:27182025-09-29 14:29:44.361Producción Académica (UCC) - Universidad Católica de Córdobafalse
dc.title.none.fl_str_mv The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
title The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
spellingShingle The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
Martín, Andrea P.
R Medicina (General)
title_short The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
title_full The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
title_fullStr The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
title_full_unstemmed The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
title_sort The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
dc.creator.none.fl_str_mv Martín, Andrea P.
Urrets Zavalía, Julio
Berra, Alejandro
Gallino, Norberto
Gómez Demel, Eduardo
Gagliardi, Julio
Mariani, Ana Lía
Baena Cagnani, Carlos E.
Urrets Zavalía, Enrique Alberto
Serra, Horacio M.
author Martín, Andrea P.
author_facet Martín, Andrea P.
Urrets Zavalía, Julio
Berra, Alejandro
Gallino, Norberto
Gómez Demel, Eduardo
Gagliardi, Julio
Mariani, Ana Lía
Baena Cagnani, Carlos E.
Urrets Zavalía, Enrique Alberto
Serra, Horacio M.
author_role author
author2 Urrets Zavalía, Julio
Berra, Alejandro
Gallino, Norberto
Gómez Demel, Eduardo
Gagliardi, Julio
Mariani, Ana Lía
Baena Cagnani, Carlos E.
Urrets Zavalía, Enrique Alberto
Serra, Horacio M.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv R Medicina (General)
topic R Medicina (General)
dc.description.none.fl_txt_mv Background: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical markers of inflammation on conjunctival cells in patients with AC. Methods: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness, increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during thirty days. They were studied by measuring clinical and immunologic parameters. Results: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped significantly in 68% and 73% of them (p < 0.0062 and [removed] Indications:19 patients with allergic conjunctivitis with symptoms of itching, tearing, burning, redness and signs of increased watery discharge, swelling, and presence of follicles. Coexisting diseases were hay fever, asthmatic bronchitis and dermatitis. Patients:19 patients, 8 males and 11 females, aged between 6 and 63 years. TypeofStudy:An open, uncontrolled study investigating the effect of Zaditen administration on biochemical markers of inflammation on conjunctival cells in patients with allergic conjunctivitis (AC). DosageDuration:One drop of 0.05% ophthalmic emulsion on both eyes topically (twice daily instillations). Duration: 30 days. One drop of 0.05% eye drops topically bid to both eyes. Duration: 30 days. Results:After 7 days of treatment, 10 (53%) patients showed improvements of their symptoms and signs (p < 0.0001). With continued treatment through day 14, symptoms control was achieved in 14 (76%) patients (p < 0.0001). Moreover, administration of 0.05% Zaditen eye drops for 30 days significantly (p < 0.0001) reduced the TSSS for each patient between days 0 and 30. Treatment with this drug had clinical effects on burning, watery discharge, and swelling, particularly, at the end of the treatment. Every other symptom was significantly reduced (p < 0.016) at any time of clinical evaluation. The effect of the treatment was also studied on the expression of different molecules on CD45 negative cells by fluorescence activated cell sorting (FACS). It is worth to note that cells studied which were obtained by conjunctival scraping never contained more than 3% of CD45+ cells. When the expression of HLA-DR, CD29 and eotaxin on EC was evaluated after the treatment, a drop in the percentage of those positive EC in 58%, 68% and 73% of patients, respectively was found. Although the variation in percentage of HLA-DR+ conjunctival EC was not significant, the percentage of CD29+ and eotaxin + EC significantly decreased (p < 0.0062 and < 0.0082, respectively) at the end of the treatment. In 9/19 patients a simultaneous drop in EC positive for CD29 and eotaxin was observed. No correlation between variations in mean fluorescent intensity and percentage of positive EC for these markers before and after the treatment was found. FreeText:All patients had a history of allergy. Different symptoms (itching, tearing, burning, redness) and signs (watery discharge increase, swelling, presence of follicles) of allergic conjunctivitis were evaluated at their enrollment (day zero) and at different times after starting treatment (7, 15 and 30 days). Symptoms and signs were classified in four stages: 0-Absent; 1-Mild; 2-Moderate and 3-Severe. The total symptoms and signs score (TSSS) for each subject were obtained by adding the values of each symptoms and signs divided by the total number of them. Samples of conjunctival scrapings were collected from both eyes of all patients treated on days 0 and 30 using a disposable plastic scoop. Tests: CD29, HLA-DR antigen, and eotaxin expression in conjunctival epithelial cells (EC). AdverseEffects:No adverse events were mentioned. AuthorsConclusions:Here, we corroborated the effectiveness of ketotifen fumarate in decreasing the symptoms and signs of AC in the majority of patients, but more importantly we showed that this drug even though was not effective in reducing the expression of HLA-DR on EC, it significantly decreased the percentage of CD29+ and eotaxin+ EC.
Fil: Martín, Andrea P. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Urrets Zavalía, Julio. Universidad Católica de Córdoba. Facultad de Ciencias Médicas; Argentina
Fil: Berra, Alejandro. Dpto. de Patología, Facultad Medicina, Universidad de Buenos Aires, Argentina
Fil: Gallino, Norberto. Inmunología, Universidad Nacional de Misiones, Argentina
Fil: Gómez Demel, Eduardo. Servicio de Oftalmología, Hospital Privado, Córdoba, Argentina
Fil: Gagliardi, Julio. Servicio de Alergia e Inmunologia, Hospital Privado, Córdoba, Argentina
Fil: Mariani, Ana Lía. Inmunología, Universidad Nacional de Misiones, Argentina
Fil: Baena Cagnani, Carlos E. Servicio de Pediatría, Hospital Infantil Municipal, Córdoba, Argentina
Fil: Urrets Zavalía, Enrique Alberto. Universidad Católica de Córdoba. Facultad de Ciencias Médicas; Argentina
Fil: Serra, Horacio M. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina
description Background: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical markers of inflammation on conjunctival cells in patients with AC. Methods: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness, increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during thirty days. They were studied by measuring clinical and immunologic parameters. Results: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped significantly in 68% and 73% of them (p < 0.0062 and [removed] Indications:19 patients with allergic conjunctivitis with symptoms of itching, tearing, burning, redness and signs of increased watery discharge, swelling, and presence of follicles. Coexisting diseases were hay fever, asthmatic bronchitis and dermatitis. Patients:19 patients, 8 males and 11 females, aged between 6 and 63 years. TypeofStudy:An open, uncontrolled study investigating the effect of Zaditen administration on biochemical markers of inflammation on conjunctival cells in patients with allergic conjunctivitis (AC). DosageDuration:One drop of 0.05% ophthalmic emulsion on both eyes topically (twice daily instillations). Duration: 30 days. One drop of 0.05% eye drops topically bid to both eyes. Duration: 30 days. Results:After 7 days of treatment, 10 (53%) patients showed improvements of their symptoms and signs (p < 0.0001). With continued treatment through day 14, symptoms control was achieved in 14 (76%) patients (p < 0.0001). Moreover, administration of 0.05% Zaditen eye drops for 30 days significantly (p < 0.0001) reduced the TSSS for each patient between days 0 and 30. Treatment with this drug had clinical effects on burning, watery discharge, and swelling, particularly, at the end of the treatment. Every other symptom was significantly reduced (p < 0.016) at any time of clinical evaluation. The effect of the treatment was also studied on the expression of different molecules on CD45 negative cells by fluorescence activated cell sorting (FACS). It is worth to note that cells studied which were obtained by conjunctival scraping never contained more than 3% of CD45+ cells. When the expression of HLA-DR, CD29 and eotaxin on EC was evaluated after the treatment, a drop in the percentage of those positive EC in 58%, 68% and 73% of patients, respectively was found. Although the variation in percentage of HLA-DR+ conjunctival EC was not significant, the percentage of CD29+ and eotaxin + EC significantly decreased (p < 0.0062 and < 0.0082, respectively) at the end of the treatment. In 9/19 patients a simultaneous drop in EC positive for CD29 and eotaxin was observed. No correlation between variations in mean fluorescent intensity and percentage of positive EC for these markers before and after the treatment was found. FreeText:All patients had a history of allergy. Different symptoms (itching, tearing, burning, redness) and signs (watery discharge increase, swelling, presence of follicles) of allergic conjunctivitis were evaluated at their enrollment (day zero) and at different times after starting treatment (7, 15 and 30 days). Symptoms and signs were classified in four stages: 0-Absent; 1-Mild; 2-Moderate and 3-Severe. The total symptoms and signs score (TSSS) for each subject were obtained by adding the values of each symptoms and signs divided by the total number of them. Samples of conjunctival scrapings were collected from both eyes of all patients treated on days 0 and 30 using a disposable plastic scoop. Tests: CD29, HLA-DR antigen, and eotaxin expression in conjunctival epithelial cells (EC). AdverseEffects:No adverse events were mentioned. AuthorsConclusions:Here, we corroborated the effectiveness of ketotifen fumarate in decreasing the symptoms and signs of AC in the majority of patients, but more importantly we showed that this drug even though was not effective in reducing the expression of HLA-DR on EC, it significantly decreased the percentage of CD29+ and eotaxin+ EC.
publishDate 2003
dc.date.none.fl_str_mv 2003-01-31
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://pa.bibdigital.ucc.edu.ar/3972/1/A_Mart%C3%ADn_UrretsZavalia_Berra_Mariani_Gallino_G%C3%B3mezDemel_Galiardo_BaenaCagnani_UrretsZavalia_Serra.pdf
url http://pa.bibdigital.ucc.edu.ar/3972/1/A_Mart%C3%ADn_UrretsZavalia_Berra_Mariani_Gallino_G%C3%B3mezDemel_Galiardo_BaenaCagnani_UrretsZavalia_Serra.pdf
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv http://pa.bibdigital.ucc.edu.ar/3972/
info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2415-3-2
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Martín, Andrea P., Urrets Zavalía, Julio ORCID: https://orcid.org/0000-0003-2267-2783 <https://orcid.org/0000-0003-2267-2783>, Berra, Alejandro, Gallino, Norberto, Gómez Demel, Eduardo, Gagliardi, Julio, Mariani, Ana Lía, Baena Cagnani, Carlos E., Urrets Zavalía, Enrique Alberto and Serra, Horacio M. ORCID: https://orcid.org/0000-0003-4979-8642 <https://orcid.org/0000-0003-4979-8642> (2003) The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. BMC Ophthalmology, 3. pp. 1-8. ISSN 1471-2415
reponame:Producción Académica (UCC)
instname:Universidad Católica de Córdoba
reponame_str Producción Académica (UCC)
collection Producción Académica (UCC)
instname_str Universidad Católica de Córdoba
repository.name.fl_str_mv Producción Académica (UCC) - Universidad Católica de Córdoba
repository.mail.fl_str_mv bibdir@uccor.edu.ar
_version_ 1844621584150560768
score 12.559606